A new Joslin-led study has shown that leptin, a hormone known mainly for regulating appetite control and energy metabolism, plays a major role in islet cell growth and insulin secretion. This finding opens up new avenues for studying leptin and its role in islet cell biology, which may lead to new treatments for diabetes.
Today’s announcement of the planned 2008 increase in Medicare premiums underscores the urgent need for congressional action on Medicare, says the American Medical Association (AMA). In CMS’ analysis of the premium increase, it is clear that growth in Medicare Advantage plans is solely responsible for the increase in the 2008 Medicare Part B premium.
Pregnant women who have very low cholesterol may face a greater risk of delivering their babies prematurely than women with more moderate cholesterol levels, a team led by the National Human Genome Research Institute (NHGRI), part of the National Institutes of Health (NIH), reported today.
A popular prostate cancer treatment called androgen deprivation therapy may encourage prostate cancer cells to produce a protein that makes them more likely to spread throughout the body, a new study by Johns Hopkins researchers suggests.
Asam Urat Flu Tulang, PJ Dewandaru is a health product promoted to treat joint pain, rheumatism and arthritis. Health Canada is advising consumers not to use the product due to concerns about possible side-effects.
Khun-Phra is a health product promoted to treat arthritis and joint pain. Health Canada is advising consumers not to use the product due to concerns about possible side-effects.
WHO Secretary-General Ban Ki-moon called on countries to work together to strengthen health systems around the world, and enable more people to access them, citing the link between health, security and development.
To accelerate the advancement of stem cell biology from bench to bedside for treatment of cardiovascular disease, the National Institutes of Health (NIH) will host the scientific symposium Cardiovascular Regenerative Medicine at the NIH Natcher Conference Center in Bethesda, Maryland.
Massachusetts General Hospital (MGH) researchers have a developed a totally new approach to treating liver failure – manipulating the immune response. If the results of the animal study can be applied in human patients, the approach may be able to keep patients alive until donor organs become available or to support liver function until the organ can regenerate itself, eliminating the need for a transplant.
New Phase II data presented today suggest that ZD4054, a novel compound in development for the treatment of men with Hormone Resistant Prostate Cancer (HRPC), could offer a promising improvement in overall survival in men with metastatic HRPC who were asymptomatic or mildly symptomatic for pain.1 Patients who received ZD4054 10mg once-daily experienced a 45 percent reduction in the risk of death compared to placebo (HR 0.55; 80 percent CI 0.41, 0.73).